蛋白酶K市場 - 全球產業規模、佔有率、趨勢、機會及預測（按治療領域、應用、最終用戶、地區和競爭格局分類，2021-2031年）

全球蛋白酶 K 市場預計將從 2025 年的 52.1 億美元成長到 2031 年的 80.9 億美元，複合年成長率為 7.61%。

作為一種穩定且廣效的絲胺酸蛋白酶，蛋白酶K廣泛應用於蛋白質消化以及DNA和RNA分離過程中的核酸酶去活化。市場成長的主要驅動力是感染疾病和遺傳性疾病發病率的上升，這使得對可靠的分子診斷檢測和基因測序的需求變得特別迫切。這種對精準臨床診斷和生命科學研究的基本需求，也支撐了樣品製備所需的高純度酵素試劑的持續需求。

根據世界衛生組織（世衛組織）的數據，預計到2024年全球將新增1080萬例結核病病例，這一數據凸顯了擴大利用這些提取酶的快速分子診斷檢測的普及範圍的迫切需求。儘管成長要素強勁，但市場仍面臨許多障礙，例如嚴格的監管標準以及分子級酵素生產高成本。這些因素可能會限制供應鏈的擴充性，並阻礙新興經濟體的消費者負擔得起。

市場促進因素

分子診斷和體外診斷 (IVD) 應用的成長是全球蛋白酶 K 市場的主要催化劑，這主要得益於該酵素在製備用於精確分析的臨床檢體中發揮的關鍵作用。隨著實驗室擴大採用分子工作流程來識別感染疾病病原體和基因異常，對用於核酸分離的高純度蛋白酶 K 的需求呈指數級成長。這種酵素在高通量診斷實驗室中至關重要，因為它能有效分解可能抑制擴增技術的污染蛋白。此類診斷的規模極為龐大；例如，羅氏公司於 2024 年 3 月發布的 2023 年年度報告顯示，該公司將在全球範圍內完成 290 億次診斷測試，這凸顯了已開發經濟體和新興經濟體醫療保健系統在樣本處理方面對可靠試劑的巨大需求。

同時，次世代定序(NGS) 技術的快速發展正在改變市場格局，對複雜基因組應用所需的高純度酵素提出了更高的要求。現代定序平台憑藉其更高的通量和靈敏度，需要不含核酸酶和蛋白質雜質的 DNA 模板，這提高了對蛋白酶 K 製劑的要求。該領域的創新得到了大量資本投資的支持。根據賽默飛世爾科技公司於 2024 年 4 月發布的《2023 年年度報告》，該公司已投資 13 億美元用於研發新技術，包括生命科學領域的技術。這種投資環境正在推動先進定序儀器的應用，進而帶動試劑的使用。 Illumina 公司於 2024 年 2 月發布的 2023 會計年度財務業績新聞稿顯示，其 NovaSeq X 儀器的出貨量為 352 台，顯示其定序能力顯著提升。這與提取酶使用量的增加密切相關。

市場挑戰

嚴格的監管標準和分子級酵素生產相關的高成本，對全球蛋白酶K市場的成長構成了重大障礙。生產高純度蛋白酶K需要先進的純化製程和嚴格控制的環境，以徹底去除核酸酶等污染物。這些嚴格的合規要求需要大量的資本投入和高昂的營運成本，直接限制了製造商高效擴展供應鏈的能力。因此，這些關鍵試劑的高昂價格阻礙了其在新興經濟體的市場滲透，而價格承受能力是獲得分子診斷的關鍵因素。

這些製造壓力帶來的廣泛影響已體現在近期行業績效指標。根據歐洲化學工業理事會（Cefic）預測，到2024年，歐洲化學和生物化學製造業的運轉率約為75%，這一數字受到高額監管負擔和營運成本的顯著限制。如此低的運轉率利用率凸顯了製造商在擴大生產規模的同時控制遵循成本所面臨的挑戰。在蛋白酶K市場，這些財務和營運方面的限制直接阻礙了該行業滿足全球診斷測試材料激增需求的能力。

市場趨勢

在生物製藥應用中，高純度和批次間一致性至關重要，這正推動全球市場從天然細菌萃取方法向重組生產方法發生重大轉變。這種轉變滿足了現代基因組工作流程的嚴格要求，提供不含動物性污染物且比天然酵素具有更高比活性的酵素。這種向先進生物製造原料的轉變已達到工業規模，並支持符合高監管標準的供應鏈。根據默克集團（Merck KGaA）2025年3月發布的2024年度報告，該公司製程解決方案部門的銷售額達到35億歐元。這一數字證實了市場對生產這些重組試劑所必需的高品質生物原料的強勁需求。

同時，高通量自動化工作站的普及推動了市場對即時用型液體製劑而非傳統凍乾粉劑的偏好。實驗室擴大採用自動化液體處理系統，以消除人工移液誤差並加快樣品處理速度，這需要穩定、即用型的酵素製劑來滿足自動化工作流程的需求。生命科學公司對自動化基礎設施的大量投資支撐了這一營運模式的轉變。根據Tecan集團於2025年3月發布的2024年度報告，該公司生命科學部門的銷售額將達到3.97億瑞士法郎，凸顯了液體處理平台的廣泛應用推動了這些專用酵素製劑的消費。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球蛋白酶K市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依治療領域（感染疾病、糖尿病、腫瘤、心臟病、腎臟病、自體免疫疾病、神經病變、其他）
  • 依應用（基因組DNA/RNA分離/純化、原位雜合反應、粒線體分離、酵素去除）
  • 依最終使用者（合約研究組織、學術機構、生技公司、診斷檢查室）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美蛋白酶K市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲蛋白酶K市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區蛋白酶K市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲蛋白酶K市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲蛋白酶K市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球蛋白酶K市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Promega Corporation
• QIAGEN NV
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Worthington Biochemical Corporation
• New England Biolabs, Inc.
• BIORON GmbH
• Sisco Research Laboratories Pvt. Ltd.
• Bioline Global Pty Ltd
• Codexis, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Proteinase K Market is projected to increase from a valuation of USD 5.21 Billion in 2025 to USD 8.09 Billion by 2031, reflecting a compound annual growth rate of 7.61%. As a stable and broad-spectrum serine protease, Proteinase K is extensively applied for protein digestion and the inactivation of nucleases during the isolation of DNA and RNA. The growth of this market is primarily driven by the rising incidence of infectious diseases and genetic disorders, which creates a critical need for robust molecular diagnostic testing and genomic sequencing. This fundamental demand for accurate clinical diagnostics and life sciences research underpins the continuous requirement for high-purity enzymatic reagents necessary for sample preparation.

According to data from the World Health Organization, tuberculosis resulted in an estimated 10.8 million incident cases globally in 2024, a statistic that highlights the urgent need to expand access to molecular rapid diagnostic tests utilizing these extraction enzymes. Despite these powerful growth drivers, the market encounters significant hurdles related to rigorous regulatory standards and the high costs involved in manufacturing molecular-grade enzymes. These factors can limit the scalability of supply chains and hinder affordability within emerging economies.

Market Driver

The growth of Molecular Diagnostic and In Vitro Diagnostic (IVD) applications serves as a primary catalyst for the Global Proteinase K Market, anchored by the enzyme's essential function in preparing clinical samples for precise analysis. As laboratories increasingly implement molecular workflows to identify infectious pathogens and genetic anomalies, the demand for high-grade Proteinase K for nucleic acid isolation has risen sharply. This enzyme efficiently digests contaminating proteins that could otherwise inhibit amplification technologies, making it vital for high-throughput diagnostic facilities. The scale of this diagnostic volume is massive; for instance, Roche reported in its 'Annual Report 2023', published in March 2024, that it delivered 29 billion diagnostic tests globally, underscoring the vast quantity of reliable reagents required for sample processing across developed and emerging healthcare systems.

Concurrently, rapid advancements in Next-Generation Sequencing (NGS) technologies are transforming the market by necessitating superior enzymatic purity for complex genomic applications. Modern sequencing platforms, offering enhanced throughput and sensitivity, require DNA templates free from nuclease and protein impurities, thereby raising the standards for Proteinase K formulations. Innovation in this sector is supported by significant capital investment; according to Thermo Fisher Scientific's 'Annual Report 2023' released in April 2024, the company invested $1.3 billion in research and development to deliver new technologies, including those benefiting life sciences. This investment environment facilitates the deployment of advanced sequencing fleets that drive reagent usage, as evidenced by Illumina's February 2024 press release regarding its fiscal year 2023 results, which reported shipments of 352 NovaSeq X instruments, signaling a strong expansion in sequencing capacity that correlates with increased extraction enzyme utilization.

Market Challenge

The rigorous regulatory standards and elevated costs associated with manufacturing molecular-grade enzymes represent a major impediment to the growth of the Global Proteinase K Market. Producing high-purity Proteinase K demands advanced purification processes and strictly controlled environments to guarantee the complete absence of contaminants such as nucleases. These strict compliance requirements necessitate substantial capital investment and high operational expenditures, which directly restrict the ability of manufacturers to efficiently scale supply chains. Consequently, the high price point of these essential reagents limits market penetration in emerging economies, where affordability is a crucial factor in accessing molecular diagnostics.

The broader consequences of these manufacturing pressures are reflected in recent industrial performance metrics. According to the European Chemical Industry Council (Cefic), the chemical and biochemical manufacturing sector in Europe operated at a capacity utilization rate of approximately 75% in 2024, a figure significantly suppressed by high regulatory burdens and operational costs. This underutilization highlights the challenges manufacturers face in expanding output while managing compliance expenses. For the Proteinase K market, such financial and operational rigidities directly hamper the industry's capacity to meet the surging global demand for diagnostic testing materials.

Market Trends

The global market is experiencing a significant shift from native fungal extraction to recombinant production methods, spurred by the critical need for superior purity and batch consistency in biopharmaceutical applications. This transition addresses the stringent requirements of modern genomic workflows by providing enzymes that are free from animal-derived contaminants and possess higher specific activity than their natural counterparts. The industrial scale of this move toward advanced biomanufacturing inputs is substantial, supporting a supply chain capable of meeting elevated regulatory standards. As noted in Merck KGaA's 'Annual Report 2024' from March 2025, the company's Process Solutions business unit generated sales of €3.5 billion, a figure that underscores the robust demand for high-grade biological raw materials essential for producing such recombinant reagents.

Simultaneously, the widespread adoption of high-throughput automated workstations is driving a market preference for ready-to-use liquid formulations over traditional lyophilized powders. Laboratories are increasingly integrating automated liquid handling systems to eliminate manual pipetting errors and accelerate sample processing speeds, necessitating enzyme formats that are stable and immediately deployable in robotic workflows. This operational evolution is evidenced by the significant capital allocated to automation infrastructure by life sciences entities. According to Tecan Group's 'Annual Report 2024', released in March 2025, the company reported sales of CHF 397 million in its Life Sciences Business segment, highlighting the extensive deployment of the liquid handling platforms that drive the consumption of these specialized enzyme formulations.

Key Market Players

• Promega Corporation
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Worthington Biochemical Corporation
• New England Biolabs, Inc.
• BIORON GmbH
• Sisco Research Laboratories Pvt. Ltd.
• Bioline Global Pty Ltd
• Codexis, Inc.

Report Scope

In this report, the Global Proteinase K Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Proteinase K Market, By Therapeutic Area

• Infectious Diseases
• Diabetes
• Oncology
• Cardiology
• Nephrology
• Autoimmune Diseases
• Neurology
• Others

Proteinase K Market, By Application

• Isolation & Purification Of Genomic DNA & RNA
• In Situ Hybridization
• Mitochondria Isolation
• Enzyme Removal

Proteinase K Market, By End User

• Contract Research Organization
• Academic Institutes
• Biotechnology Companies
• Diagnostic Laboratories

Proteinase K Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Proteinase K Market.

Available Customizations:

Global Proteinase K Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Proteinase K Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutic Area (Infectious Diseases, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune Diseases, Neurology, Others)
  • 5.2.2. By Application (Isolation & Purification Of Genomic DNA & RNA, In Situ Hybridization, Mitochondria Isolation, Enzyme Removal)
  • 5.2.3. By End User (Contract Research Organization, Academic Institutes, Biotechnology Companies, Diagnostic Laboratories)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Proteinase K Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutic Area
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Proteinase K Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutic Area
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Proteinase K Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutic Area
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Proteinase K Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutic Area
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Proteinase K Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutic Area
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Proteinase K Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutic Area
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Proteinase K Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutic Area
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Proteinase K Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutic Area
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Proteinase K Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutic Area
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Proteinase K Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutic Area
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Proteinase K Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutic Area
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Proteinase K Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutic Area
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Proteinase K Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutic Area
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Proteinase K Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutic Area
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Proteinase K Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapeutic Area
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Proteinase K Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapeutic Area
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Proteinase K Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutic Area
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Proteinase K Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutic Area
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Proteinase K Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutic Area
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Proteinase K Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapeutic Area
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Proteinase K Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutic Area
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Proteinase K Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutic Area
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Proteinase K Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutic Area
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Proteinase K Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutic Area
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Proteinase K Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Promega Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. QIAGEN N.V.
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. F. Hoffmann-La Roche Ltd
• 15.5. Worthington Biochemical Corporation
• 15.6. New England Biolabs, Inc.
• 15.7. BIORON GmbH
• 15.8. Sisco Research Laboratories Pvt. Ltd.
• 15.9. Bioline Global Pty Ltd
• 15.10. Codexis, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer